Penserra Capital Management LLC Immunovant, Inc. Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.65 $2,251 - $3,762	666 Added 22.72%	3,597 $14,000
Q1 2022 May 13, 2022	SELL	$5.06 - $8.77 $4,862 - $8,427	-961 Reduced 24.69%	2,931 $16,000
Q4 2021 Feb 15, 2022	SELL	$7.33 - $9.32 $21,381 - $27,186	-2,917 Reduced 42.84%	3,892 $33,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $34,972 - $56,724	-4,989 Reduced 42.29%	6,809 $59,000
Q2 2021 Aug 12, 2021	SELL	$9.4 - $16.85 $44,443 - $79,666	-4,728 Reduced 28.61%	11,798 $124,000
Q1 2021 May 13, 2021	SELL	$13.08 - $49.6 $72,960 - $276,668	-5,578 Reduced 25.24%	16,526 $265,000
Q4 2020 Feb 12, 2021	BUY	$36.36 - $52.71 $701,020 - $1.02 Million	19,280 Added 682.72%	22,104 $1.02 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $63,850 - $109,853	2,824 New	2,824 $106,000

211

66M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.